Mandate

Vinge advises Hansa Medical in connection with directed share issue

October 24, 2016

The board of directors of Hansa Medical proposes a capital raising through a directed share issue, whereby the company will receive approximately SEK 185 million.

The share issue is directed to selected international specialist investors as well as Swedish institutional and strategic investors. The issue proceeds will primarily be used to finance the development process of the drug candidate IdeS up to an application for market authorization of IdeS for treatment in connection with kidney transplantation. The share issue is fully subscribed for in accordance with agreements executed with the selected investors. Shareholders representing approximately 45 percent of Hansa Medical’s shares and votes have undertaken to vote in favor of the board’s proposal for the share issue at an extraordinary general meeting.

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team consists of Dain Hård Nevonen, Erik Sjöman and Nils Fredrik Dehlin.

Related

Vinge advises Vimian in connection with new RCF and issuance of senior unsecured bonds

Vinge advises Vimian Group AB (publ) (“Vimian”) in connection with a new EUR 330 million multicurrency revolving facility agreement and its issuance of senior unsecured bonds in an amount of EUR 150 million (within a framework of EUR 250 million)
May 28, 2025

Vinge represents Alrik Technologies in connection with their latest funding round

Vinge has represented Alrik Technologies in connection with their latest funding round led by People Ventures, with Pi Labs doubling down on their investment.
May 27, 2025

Vinge advises Trinax in connection with the acquisition of Struqtur

Trinax, a Helix Kapital portfolio company, has acquired Struqtur, a Swedish company offering a comprehensive cloud-based software solution for time reporting, project management and work orders.
May 26, 2025